Facebook Linkedin RSS Twitter Youtube
Home 2018

Bladder cancer

Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M
Cancer

Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M

Lasers and Gold Help Fry Bladder Cancer
Cancer

Lasers and Gold Help Fry Bladder Cancer

Immunotherapy’s Ineffectiveness toward Bladder Cancer Uncovered
Cancer

Immunotherapy’s Ineffectiveness toward Bladder Cancer Uncovered

Single Urine Biomarker Assay Predicts Recurrence of Bladder Cancer
Cancer

Single Urine Biomarker Assay Predicts Recurrence of Bladder Cancer

LifeArc, Dstl, CDRD Partner to Identify Targets for Multidrug-Resistant Infections
Drug Discovery

LifeArc, Dstl, CDRD Partner to Identify Targets for Multidrug-Resistant Infections

NCI to Test Eleven’s Vicinium Combined with AstraZeneca’s Imfinzi against NMIBC
Cancer

NCI to Test Eleven’s Vicinium Combined with AstraZeneca’s Imfinzi against NMIBC

Merck KGaA, Pfizer PD-L1 mAb Wins Accelerated FDA Nod for Urothelial Carcinoma
Drug Discovery

Merck KGaA, Pfizer PD-L1 mAb Wins Accelerated FDA Nod for Urothelial Carcinoma

Roche PD-L1 mAb Misses Primary Endpoint in Phase III Urothelial Carcinoma Study
Drug Discovery

Roche PD-L1 mAb Misses Primary Endpoint in Phase III Urothelial Carcinoma Study

MDxHealth Licenses Cancer Methylation Visualization Platform from Ghent University
Cancer

MDxHealth Licenses Cancer Methylation Visualization Platform from Ghent University

BioClin Raises $30M to Expand Clinical Development of FGFR3 mAb
Cancer

BioClin Raises $30M to Expand Clinical Development of FGFR3 mAb

1234...9Page 3 of 9
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.